Curium, a world leader in nuclear medicine, today announced that in Estonia, Finland, Latvia, and Sweden, PYLCLARI® is now ...

Curium introduces innovative 18F-PSMA PET radiopharmaceutical, Pylclari to treat prostate cancer in Estonia, Finland, Latvia, & Sweden: Paris, France Wednesday, January 29, 2025, ...

The grant will be used by Craig Forrest, Ph.D. to help reveal the functions of the viral protein known as latency-associated nuclear antigen (LANA). The new research will focus on the role of LANA ...

Precise visualization of the trophoblast cell surface antigen 2 (Trop2 ... published in the December 2024 issue of The Journal of Nuclear Medicine. Trop2 has garnered interest among cancer ...